Clinical Trial Update: Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating pirfenidone for progressive interstitial lung disease associated with clinically amyopathic dermatomyositis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis
• Interstitial Lung Disease

Drugs mentioned

• Esbriet (pirfenidone)

Snippet

Sponsor: RenJi Hospital | Conditions: Dermatopolymyositis, Interstitial Lung Disease | Phase 4 | Status: UNKNOWN